Editor’s Choice: Rare Disease Events and Finding Growth Through Adversity

The Dog Days Are Back

Is it hot or what!? Whether you’re trying to catch a tan or stay cool, we have a fresh dose of weekly content in Editor’s choice. There are new possible treatments for both sickle cell disease and myelofibrosis this week, and we will also talk about this year’s NORD conference and a cancer survivor’s new project. You won’t want to miss this weeks hot topics.

[one_half]

 

[/one_half] [one_half_last]

Antibodies: The Key to Fighting Sickle Cell Anemia? Approval Could be Just Months Away

 

 

 

An antibody-style drug in development from Novartis has the potential to alleviate some of the worst complications of sickle cell disease—and this drug could get cleared a lot more quickly than you think.[/one_half_last] [one_half]

 

[/one_half] [one_half_last]

Catalysts for Change and Guidance for Growth: Terri’s Story

 

 

 

A cancer survivor uses her experience to form a new organization that allows patients and survivors to give back to their communities.

[/one_half_last] [one_half]

 

[/one_half] [one_half_last]

NORD 2019 Living Stronger Forum Highlights

 

 

 

In this story we talk about some of the highlights from our coverage of this year’s National Organization for Rare Disorders conference.
[/one_half_last] [one_half]

 

[/one_half] [one_half_last]

Huntsman Lab Research Team Discovers that Selinexor May Benefit Myelofibrosis Patients Who have No Other Curative Options

 

 

Researchers discover a new viable treatment for patients suffering from myelofibrosis.
[/one_half_last] [one_half]


Do you have a rare disease experience of your own? Share with us here.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email
Close Menu